Thursday, November 02, 2017 3:46:35 PM
Could someone please clarify timeline.
Vancouver, B.C. and Boston, MA,
September 27,2017
–
Imagin Medical, Inc.
(CSE: IME) (OTC PINK: IMEXF) (Frankfurt/Stuttgart Stock Exchanges: DPD2) (the “Company”)announced today that the University of Rochester (UR)Research Study Review Board RSRBhas approved the first in human study using the company’s i/Blue Imaging
System. Recruitment of subjects will begin immediately and continue until the study is completed, which is expected to be a 3-month process. More information can be found on www.clinicaltrials.com.
3-month process for completion of enrollment OR completion of study/trial (December 2018 as per clinicaltrials.gov).
Estimated Enrollment: 10
Anticipated Study Start Date: October 1, 2017
Estimated Study Completion Date: December 1, 2018
Estimated Primary Completion Date: October 1, 2018 (Final data collection date for primary outcome measure)
Thanks
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM